Prospect News: News for MGI Pharma Inc.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with M > All stories on MGI Pharma Inc.

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

MGI Pharma Inc.

1/28/2008	SS	Eisai acquisition of MGI Pharma nears completion
1/23/2008	SS	Eisai announces subsequent offer for MGI Pharma shares
1/17/2008	SS	Eisai, MGI Pharma merger clears waiting period hurdle
12/31/2007	CV	MGI Pharma subordinated notes to be convertible due to merger
12/21/2007	SS	Eisai tender offer for MGI Pharma to end Jan. 22
12/10/2007	CV	Market Commentary: WaMu bringing big deal; A&P watching P's & Q's; Millennium up on drug tests; MGI up on merger
12/10/2007	CV	Market Commentary: WaMu bringing big deal; A&P watching P's & Q's; Millennium up on drug tests; MGI up on merger
12/10/2007	SS	Eisai to acquire MGI Pharma for $3.9 billion
12/10/2007	SS	Market Commentary: Washington Mutual restructures; UBS, MBIA get cash infusions; MGI, Adams merge with foreign drug firms
11/29/2007	SS	MGI Pharma to consider strategic alternatives
11/29/2007	SS	Market Commentary: E*Trade gets $2.5 billion cash infusion; VeraSun, U.S. BioEnergy shares climb; MGI seeks alternatives
11/29/2007	CV	Market Commentary: E*Trade down on cash infusion; MGI Pharma up as options search begins; WCI falls with housing prices
11/27/2006	SS	Ford shares, preferreds skid; Nasdaq, LSE slip; biotechs lower; Raytheon drops; Ventas falls
10/24/2006	BKBT	MGI Pharma gets $75 million revolver
10/19/2006	BT	JMP keeps MGI at underperform
10/19/2006	BT	MGI Pharma at buy from Merrill
10/18/2006	BT	MGI Pharma ends quarter with $127 million; company continues to predict operating loss
10/13/2006	BT	Merrill keeps MGI at market underperform
10/13/2006	BT	MGI rated at buy by Merrill
9/26/2006	BT	Merrill reiterates MGI Pharma at buy
8/10/2006	BT	MGI Pharma: Dacogen receives orphan-drug status for patients with acute myeloid leukemia
7/26/2006	BT	MGI Pharma rated at buy by Merrill
7/20/2006	CV	Market Commentary: Intel, Ford, Barnes fall on earnings weakness; New River quiet on debut; Essex plans $130 million deal
7/20/2006	BT	MGI maintained at buy by Merrill
7/20/2006	BT	JMP cuts MGI to market underperform
7/19/2006	BT	MGI Pharma reports $19.4 million second quarter net loss
7/10/2006	BT	MGI Pharma maintained at market perform by JMP
7/6/2006	BT	MGI kept at buy by Merrill
7/6/2006	BT	MGI Pharma, Cilag form license agreement to develop Dacogen for Injection
6/22/2006	BT	Market Commentary: Gene Logic plunges 36%; ISTA off; MedImmune convertible on deck; American Medical issues higher
6/21/2006	BT	Merrill maintains MGI Pharma at buy
6/5/2006	BT	MGI reports Aloxi alone, in combination cuts side effects of chemotherapy
5/26/2006	BT	MGI Pharma says Dacogen available commercially in United States
5/26/2006	BT	SuperGen earns $20 million Dacogen injection milestone
5/25/2006	BT	SuperGen to use Dacogen income as 'financial engine' to develop new clinical candidates
5/4/2006	BT	JMP reiterates MGI at market perform
5/4/2006	CV	Market Commentary: Bausch and Lomb up dollar-neutral on debt tenders; JDS Uniphase falls outright on poor guidance
5/3/2006	BT	Market Commentary: MGI, SuperGen get nod from FDA for Dacogen; Impax stock climbs on FDA OK of generic Colestid
5/3/2006	CV	Market Commentary: Cephalon falls, PDL widens on results; NPS falls, MGI climbs on FDA news; XM firm despite lawsuits
5/3/2006	BT	FDA approves SuperGen, MGI Pharma's Dacogen for injection to treat patients with myelodysplastic syndromes
5/3/2006	BT	MGI rated at buy by Merrill
4/20/2006	BT	MGI stays at market perform rating from JMP
4/18/2006	BT	MGI Pharma says Dacogen injections more effective than supportive care alone
4/13/2006	BT	Merrill rates gives MGI buy rating
4/13/2006	BT	MGI expects first quarter revenues of $78 million, decreased Aloxi sales
4/13/2006	BT	MGI Pharma submits new drug application for Saforis to FDA
4/6/2006	BT	Market Commentary: Amgen a drag on biotech sector; Medarex follow-on seen on deck; Oscient up on PIPE after-hours
3/21/2006	BT	JMP reiterates MGI at market perform
3/20/2006	BT	MGI Pharma starts Aquavan sedation injection program
2/9/2006	BT	JMP puts MGI at market perform
2/9/2006	BT	MGI Pharma maintained at buy by Merrill
2/8/2006	CV	Market Commentary: Citadel retraces some gains; Qwest flat but adds on hedge; MGI better; Oil States lower; Pier 1 prices
1/19/2006	CV	Market Commentary: Advanced Micro, Cypress gain, but Intel weaker; Hutchinson prices upsized $225 million deal
1/19/2006	BT	MGI Pharma given outperform rating by Thomas Weisel
1/19/2006	BT	Market Commentary: Endo Pharmaceuticals prices $417.75 million secondary stock sale; Procyon to merge with Cellpep
1/12/2006	BT	JMP cuts MGI Pharma to market perform
1/10/2006	BT	Merrill maintains MGI at buy
1/10/2006	CV	Market Commentary: LifePoint Hospitals, MGI Pharma convertibles weaker on lower guidance; Cephalon jumps; GM mixed
12/22/2005	BT	JMP reiterates MGI at outperform
12/21/2005	BT	MGI Pharma: Phase 2 study of Aquavan for sedation shows promising results
12/21/2005	BT	MGI maintained by Merrill at buy
12/21/2005	BT	Market Commentary: Biopure bleeds off 13% after deal; MGI rises 11%; Sinovac up 8%; Novavax plunges 14% post close
12/16/2005	BT	Merrill maintains MGI at buy
12/15/2005	BT	MGI, SuperGen answer FDA questions on Dacogen
12/14/2005	BT	MGI Pharma maintained by Merrill at buy
12/12/2005	BT	MGI Pharma, SuperGen data show Dacogen may help MDS, AML, CML patients
11/29/2005	BTCV	MGI Pharma gets tenders for $67.9 million Guilford convertibles
11/16/2005	BT	JMP reiterates MGI at market outperform
11/15/2005	BT	MGI Pharma still a buy, says Merrill Lynch
10/27/2005	BT	Merrill reiterates MGI at buy
10/27/2005	CV	Market Commentary: GM bonds lower, credit widens on bankruptcy scare; Digital River plunges; Par Pharma in
10/26/2005	BT	MGI Pharma, SuperGen: Dacogen injection under review in U.S., Europe
10/21/2005	CV	Market Commentary: Wyeth holds up; Ford drops, but GM bonds move higher; Schlumberger off
10/20/2005	BT	JMP lowers MGI Pharma price target
10/20/2005	BT	Merrill Lynch maintains MGI Pharma at buy
10/20/2005	CV	Market Commentary: Convertibles market reverses course after strong start; Cypress pulled down; Amgen, biotechs weaker
10/20/2005	BTCV	MGI Pharma tenders for newly acquired Guilford Pharmaceuticals convertible notes
10/19/2005	BT	JMP maintains MGI at outperform, lowers price target
10/17/2005	BT	MGI Pharma received Merrill buy rating
10/3/2005	BT	Amylin sales looking up as Biogen may face downside, Merrill report says
10/3/2005	BTCV	MGI Pharma completes Guilford acquisition, plans to tender for convertibles
9/28/2005	BT	MGI Pharma price target cut by Merrill
9/2/2005	BT	MGI Pharma kept at buy, Merrill says
9/2/2005	BT	MGI Pharma reiterated at market outperform by JMP
9/2/2005	CV	Market Commentary: Albertson's mandatories lag as stock surges; Northwest Airlines, Delta weaken further
8/30/2005	BT	MGI kept by JMP at market outperform
7/22/2005	BT	MGI kept by JMP at market outperform
7/22/2005	BT	MGI Pharma price target cut by Merrill
7/21/2005	BT	Market Commentary: Adams IPO zooms; Accentia stalls, again; Guilford up on MGI Pharma merger; Momenta on tap; Isis rises
7/21/2005	CV	Market Commentary: Cheniere Energy to price $300 million deal; selling hits convertibles as Treasuries slump
7/21/2005	BTCV	MGI Pharma to "extinguish" Guilford Pharmaceuticals convertibles upon acquisition
7/14/2005	BT	MGI Pharma held by Bear Stearns at outperform
7/11/2005	BT	Merrill biotech analysts see interest in sector ahead of second quarter earnings
9/1/2004	CV	Market Commentary: Ford, GM slide on sales data, production cuts; MGI Pharma acquisitions move convertibles up
3/2/2004	CV	MGI Pharma greenshoe exercised, raising convertibles to $260 million
2/26/2004	CV	Market Commentary: Calpine slides on earnings; Toys R Us mandatory soars on stock upgrade; MGI up 0.25 point
2/26/2004	CV	New Issue: MGI Pharma $225 million proceeds cash-to-zero converts at 2.25% yield, up 30%
2/25/2004	CV	Market Commentary: Level 3 gains 2 points on massive credit spread blowout; Adelphia whipsaws, ends in 40s
2/24/2004	CV	MGI Pharma $200 million proceeds discount cash-to-zero convert talked at 2.0-2.5% yield, up 30-35%
2/24/2004	CV	Market Commentary: Calpine drops sharply after junk bond deal goes sour; BankUnited prices $100 million

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.